Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review.

Tytuł:
Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review.
Autorzy:
Marjanski T; Thoracic Surgery Department, Medical University of Gdansk, Sklodowskiej-Curie 3A, 80-211 Gdansk, Poland.
Dziedzic R; Thoracic Surgery Department, Medical University of Gdansk, Sklodowskiej-Curie 3A, 80-211 Gdansk, Poland.
Kowalczyk A; Department of Oncology and Radiotherapy, Medical University of Gdansk, Sklodowskiej-Curie 3A, 80-211 Gdansk, Poland.
Rzyman W; Thoracic Surgery Department, Medical University of Gdansk, Sklodowskiej-Curie 3A, 80-211 Gdansk, Poland.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Nov 12; Vol. 22 (22). Date of Electronic Publication: 2021 Nov 12.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung/*drug therapy
ErbB Receptors/*antagonists & inhibitors
Lung Neoplasms/*drug therapy
Molecular Targeted Therapy/*methods
Protein Kinase Inhibitors/*therapeutic use
Anaplastic Lymphoma Kinase/metabolism ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/surgery ; Diarrhea/chemically induced ; ErbB Receptors/metabolism ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/surgery ; Nausea/chemically induced ; Neoadjuvant Therapy/methods ; Protein Kinase Inhibitors/adverse effects
References:
J Clin Oncol. 2012 Aug 1;30(22):2731-8. (PMID: 22753915)
Surg Case Rep. 2018 Mar 9;4(1):19. (PMID: 29524063)
N Engl J Med. 2018 Nov 22;379(21):2027-2039. (PMID: 30280657)
Cancer Treat Res Commun. 2021;28:100439. (PMID: 34333246)
Ann Thorac Cardiovasc Surg. 2020 Dec 20;26(6):303-310. (PMID: 32611931)
J Clin Oncol. 2008 Jul 20;26(21):3552-9. (PMID: 18506026)
J Thorac Cardiovasc Surg. 2019 Jan;157(1):362-373.e8. (PMID: 30482524)
N Engl J Med. 2009 Sep 3;361(10):947-57. (PMID: 19692680)
Cancer Chemother Pharmacol. 2019 Jun;83(6):1195-1196. (PMID: 30863883)
Cancer Discov. 2016 Dec;6(12):1382-1399. (PMID: 27663893)
N Engl J Med. 2011 Aug 4;365(5):395-409. (PMID: 21714641)
Pharmaceuticals (Basel). 2020 Dec 18;13(12):. (PMID: 33352844)
J Thorac Oncol. 2018 Mar;13(3):413-425. (PMID: 29191776)
J Cancer Res Clin Oncol. 2015 Jan;141(1):61-8. (PMID: 25086987)
Clin Lung Cancer. 2017 Sep;18(5):472-479. (PMID: 28373069)
Radiology. 2021 Mar;298(3):550-566. (PMID: 33434111)
J Clin Oncol. 2019 Sep 1;37(25):2235-2245. (PMID: 31194613)
Clin Lung Cancer. 2018 Mar;19(2):e151-e161. (PMID: 29174221)
Cancer Sci. 2014 Dec;105(12):1584-90. (PMID: 25287435)
Crit Rev Oncol Hematol. 2021 Apr;160:103305. (PMID: 33757838)
Oncotarget. 2017 Dec 16;9(10):9480-9488. (PMID: 29507704)
Mol Cell Oncol. 2015 Jun 01;2(4):e1004969. (PMID: 27308503)
J Clin Oncol. 2014 Sep 1;32(25):2780-7. (PMID: 25071109)
J Thorac Oncol. 2009 Nov;4(11):1380-8. (PMID: 19861907)
Eur Respir Rev. 2017 Jan 3;26(143):. (PMID: 28049126)
J Thorac Oncol. 2014 Feb;9(2):154-62. (PMID: 24419411)
Diagnostics (Basel). 2021 Sep 17;11(9):. (PMID: 34574036)
Lancet Respir Med. 2018 Nov;6(11):863-873. (PMID: 30150014)
Lancet. 2021 Oct 9;398(10308):1344-1357. (PMID: 34555333)
BMC Cancer. 2017 Jun 12;17(1):412. (PMID: 28606126)
J Thorac Oncol. 2019 Apr;14(4):726-731. (PMID: 30408570)
Front Pharmacol. 2020 Jun 12;11:891. (PMID: 32595510)
Am Soc Clin Oncol Educ Book. 2020 May;40:372-384. (PMID: 32421452)
Lancet. 2009 Aug 1;374(9687):379-86. (PMID: 19632716)
Ann Transl Med. 2020 Jun;8(12):770. (PMID: 32647695)
N Engl J Med. 2018 Jan 11;378(2):113-125. (PMID: 29151359)
Future Oncol. 2021 Nov;17(31):4045-4055. (PMID: 34278827)
JTO Clin Res Rep. 2021 Aug 26;2(10):100221. (PMID: 34746882)
Lancet Oncol. 2020 Nov;21(11):1413-1422. (PMID: 32979984)
JAMA Netw Open. 2019 Jul 3;2(7):e196879. (PMID: 31290993)
Cancer Manag Res. 2019 May 07;11:4109-4118. (PMID: 31190983)
N Engl J Med. 2020 Feb 6;382(6):503-513. (PMID: 31995683)
Clin Transl Sci. 2021 May;14(3):919-933. (PMID: 33382906)
Lancet Oncol. 2016 Dec;17(12):1683-1696. (PMID: 27836716)
N Engl J Med. 2014 Dec 4;371(23):2167-77. (PMID: 25470694)
N Engl J Med. 2009 Sep 3;361(10):958-67. (PMID: 19692684)
Cancer Control. 2016 Oct;23(4):338-346. (PMID: 27842323)
Expert Rev Anticancer Ther. 2013 Jun;13(6):729-36. (PMID: 23506556)
Clin Adv Hematol Oncol. 2011 Nov;9(11):824-36. (PMID: 22252615)
Eur Respir J. 2009 Jul;34(1):17-41. (PMID: 19567600)
J Chemother. 2015 Feb;27(1):40-51. (PMID: 24724908)
Front Oncol. 2021 Mar 17;11:655856. (PMID: 33816312)
J Thorac Cardiovasc Surg. 2021 Feb;161(2):434-442.e2. (PMID: 32340810)
Cancer J. 2020 Nov/Dec;26(6):517-524. (PMID: 33298723)
Onco Targets Ther. 2016 Mar 22;9:1735-41. (PMID: 27042123)
J Clin Oncol. 2015 Dec 1;33(34):4007-14. (PMID: 26324372)
J Clin Oncol. 2009 Sep 10;27(26):4232-5. (PMID: 19667260)
Medicine (Baltimore). 2016 Mar;95(9):e3008. (PMID: 26945426)
Cancer Immunol Res. 2014 Sep;2(9):846-56. (PMID: 24872026)
Lancet. 2014 May 3;383(9928):1561-71. (PMID: 24576776)
Lung Cancer. 2014 Feb;83(2):231-9. (PMID: 24332320)
Ann Transl Med. 2021 Mar;9(6):493. (PMID: 33850890)
Lancet Oncol. 2018 Jan;19(1):139-148. (PMID: 29174310)
J Oncol. 2009;2009:849051. (PMID: 19584908)
Chest. 2013 May;143(5 Suppl):e166S-e190S. (PMID: 23649437)
Asia Pac J Clin Oncol. 2018 Feb;14(1):23-31. (PMID: 28464435)
Curr Oncol. 2014 Dec;21(6):329-36. (PMID: 25489260)
J Hematol Oncol. 2015 May 17;8:54. (PMID: 25981169)
Curr Oncol. 2015 Apr;22(2):123-32. (PMID: 25908911)
Cancer Immunol Immunother. 2021 Sep 20;:. (PMID: 34542660)
Crit Rev Oncol Hematol. 2019 Feb;134:56-64. (PMID: 30771874)
Cancers (Basel). 2021 Apr 12;13(8):. (PMID: 33921237)
Lancet. 2017 Jul 1;390(10089):29-39. (PMID: 28501140)
Jpn J Clin Oncol. 2013 Jun;43(6):664-8. (PMID: 23585689)
Thorac Surg Clin. 2015 Nov;25(4):523-8. (PMID: 26515952)
Oncologist. 2019 Feb;24(2):157-e64. (PMID: 30158288)
Ann Thorac Surg. 2018 Mar;105(3):924-929. (PMID: 29258674)
Eur J Cancer. 2018 Mar;91:92-98. (PMID: 29413968)
J Thorac Oncol. 2013 Jul;8(7):823-59. (PMID: 23552377)
J Thorac Oncol. 2016 Jan;11(1):39-51. (PMID: 26762738)
Cancers (Basel). 2021 Oct 09;13(20):. (PMID: 34680195)
J Clin Oncol. 2019 Jan 10;37(2):97-104. (PMID: 30444685)
J Thorac Dis. 2020 Oct;12(10):5324-5335. (PMID: 33209366)
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535. (PMID: 28404761)
N Engl J Med. 2020 Oct 29;383(18):1711-1723. (PMID: 32955177)
Jpn J Clin Oncol. 2016 Apr;46(4):291-8. (PMID: 26826719)
J Thorac Cardiovasc Surg. 2020 Nov;160(5):1376-1382. (PMID: 32763029)
Lancet Oncol. 2012 Mar;13(3):239-46. (PMID: 22285168)
J Clin Med. 2020 Apr 27;9(5):. (PMID: 32349387)
Oncol Rep. 2021 Jan;45(1):13-28. (PMID: 33200229)
Curr Opin Oncol. 2021 Jan;33(1):55-58. (PMID: 33165003)
J Thorac Oncol. 2017 Apr;12(4):633-643. (PMID: 28007626)
Contributed Indexing:
Keywords: ALK-TKIs; EGFR-TKIs; adverse events; complications; lung cancer; neoadjuvant therapy; non-small cell lung cancer; safety; surgery; toxicity
Substance Nomenclature:
0 (Protein Kinase Inhibitors)
EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
EC 2.7.10.1 (ErbB Receptors)
Entry Date(s):
Date Created: 20211127 Date Completed: 20211220 Latest Revision: 20211220
Update Code:
20240104
PubMed Central ID:
PMC8622767
DOI:
10.3390/ijms222212244
PMID:
34830123
Czasopismo naukowe
New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were published yet. The current narrative review proves that targeted therapies are safe in neoadjuvant approach. Unsurprisingly, administration of therapy is related to an acceptable toxicity profile. Severe adverse events' rate that rarely compromises outcomes of patients with advanced lung cancer is not that commonly accepted in early lung cancer as it may lead to missing the chance of curative surgery. Among those complications, the most important factors that may limit the use of targeted therapies are severe respiratory adverse events precluding the resection occurring after treatment with some anaplastic lymphoma kinase and rarely after epidermal growth factor receptor tyrosine kinase inhibitors. At this point, in the presented literature assessing the feasibility of neoadjuvant therapies with anaplastic lymphoma kinase and epidermal growth factor receptor tyrosine kinase inhibitors, we did not find any unexpected intraoperative events that would be of special interest to a thoracic surgeon. Moreover, the postoperative course was associated with typical rate of complications.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies